CymaBay begins phase 3 liver disease study
14th August 2023 Uncategorised 0IDEAL study aims to determine the impact of seladelpar on alkaline phosphatase levels More: CymaBay begins phase 3 liver disease study Source: News
read more
IDEAL study aims to determine the impact of seladelpar on alkaline phosphatase levels More: CymaBay begins phase 3 liver disease study Source: News
read moreThe purchased therapies concerned are Cardioxane, Totect, Ethyol and Savene More: CNX acquires four cancer drugs from Clinigen Source: News
read moreAnother round of layoffs hits BMS, with 100+ people impacted after earnings miss mbayer Fri, 08/11/2023 – 14:24 More: Another round of layoffs hits BMS, with 100+ people impacted after earnings miss Source: fierce
read moreAmylyx’s ALS drug Relyvrio gets off the ground as company eyes new brain disorder aliu Fri, 08/11/2023 – 10:30 More: Amylyx's ALS drug Relyvrio gets off the ground as company eyes new brain disorder Source: fierce
read moreSupreme Court blocks Purdue Pharma’s bankruptcy settlement, threatening immunity to Sackler family kdunleavy Fri, 08/11/2023 – 10:22 More: Supreme Court blocks Purdue Pharma's bankruptcy settlement, threatening immunity to Sackler family Source: fierce
read moreEndo sues Zydus in attempt to block its generic version of Chantix zbecker Fri, 08/11/2023 – 09:26 More: Endo sues Zydus in attempt to block its generic version of Chantix Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals